Open AccessModern principles of diagnosis and treatment of severe traumatic brain injury
Author(s) -
V.І. Cherniy,
Т.V. Cherniy
Publication year - 2021
Publication title -
medicina neotložnyh sostoânij
Language(s) - English
Resource type - Journals
eISSN - 2307-1230
pISSN - 2224-0586
DOI - 10.22141/2224-0586.17.5.2021.240700
Subject(s) - traumatic brain injury , medicine , encephalopathy , cerebral blood flow , ischemia , citicoline , intensive care , hypoxia (environmental) , cerebral perfusion pressure , intensive care unit , intensive care medicine , anesthesia , psychiatry , chemistry , organic chemistry , oxygen
Traumatic brain injury (TBI) is a heterogeneous syndrome that includes various types of trauma. About 10–15 % of patients have severe TBI, accompanied by high rates of disability and mortality. Currently, the methods of intensive care from the standpoint of evidence-based medicine are widely used for their treatment. Along with intensive care, the comprehensive cytoprotective program using Neurocitin®, which contains citicoline and electrolytes, is of great importance. Neurocitin® has a combined effect aimed at correcting metabolic and volemic disorders, namely, maintaining adequate cerebral perfusion, timely elimination of water-electrolyte disorders, energy supply of brain tissues and protection of the neurovascular unit from damage. Lactate in the composition of Neurocitin® provides a detoxification effect, preserves and increases the energy supply of neurons, improves metabolism, cerebral blood flow and neuronal activity. For the treatment of TBI, the neurometabolic drug of ethylmethylhydroxypyridine succinate (Lodixem®) is also used. Lodixem® normalizes cerebral blood flow, provides an earlier resolution of post-traumatic encephalopathy and restoration of consciousness, leads to a decrease in the severity of endogenous intoxication syndrome, the elimination of pathological vicious circles that arise against the background of hypoxia, ischemia and energy deficiency in various organs and tissues.